Liav Abraham - Citigroup Global Markets
Last quote by Liav Abraham
While today's results are likely to reassure investors following a turbulent past several months for Teva, execution over the longer term is required to alleviate investor concerns.feedback
Feb 13 2017
Liav Abraham has most recently been quoted in an article called Citi downgrades Mylan, says EpiPen price scrutiny to continue even under GOP administration. Liav Abraham said, “We anticipate ongoing net pricing pressure on EpiPen as public and political scrutiny on the franchise continues. With valuation currently roughly in line with the peer group average, we see limited potential for meaningful multiple expansion.”. Liav Abraham has been quoted a grand total of 4 times in 3 articles.
Take our quote verification challenge and find out !
Quotes by Liav Abraham
Jan 05 2017
We anticipate ongoing net pricing pressure on EpiPen as public and political scrutiny on the franchise continues. With valuation currently roughly in line with the peer group average, we see limited potential for meaningful multiple expansion.feedback
Apr 05 2016
I think the fallout and the decline in share price that you see in Allergan today reflects investor concerns regarding the transaction and investors thinking about the future of Allergan as a stand-alone entity, Squawk on the Street.feedback
Apr 05 2016
It is certainly aimed squarely at the Pfizer transactions, but there are other more broad ramifications here that will affect additional transactions going forward. Companies will have to consider those. It will also affect transactions that have already potentially been undertaken because of some other implications of the rules that have been set forth, particularly as it pertains to earnings stripping.feedback
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided